Files Julia A, Stan Daniela L, Allen Summer V, Pruthi Sandhya
Division of Women's Health Internal Medicine, Mayo Clinic in Arizona, 13737 North 92nd Street, Scottsdale, AZ 85260, USA.
Womens Health (Lond). 2012 Nov;8(6):635-46. doi: 10.2217/whe.12.56.
The development of pharmacologic agents for the prevention of breast cancer is a significant milestone in medical and laboratory research. Despite these advances, the endorsement of preventive options has become challenging and complex, as physicians are expected to counsel and tailor their recommendations using a personalized approach taking into account medical comorbidities, degree of risk and patient preferences. This article provides a comprehensive overview of the major breast cancer prevention trials, review of the pharmacologic options available for breast cancer prevention, and strategies for integrating chemoprevention of breast cancer in high-risk women into clinical practice.
用于预防乳腺癌的药物制剂的研发是医学和实验室研究中的一个重要里程碑。尽管取得了这些进展,但对预防方案的认可已变得具有挑战性且复杂,因为人们期望医生采用个性化方法提供咨询并调整建议,同时考虑到合并症、风险程度和患者偏好。本文全面概述了主要的乳腺癌预防试验,回顾了可用于乳腺癌预防的药物选择,以及将高危女性乳腺癌化学预防纳入临床实践的策略。